Concord Biotech expects growth to return in FY27 after profit dropped 30%
The API maker's net profit fell to ₹259 crore in FY26 as geopolitical disruptions hurt sales. Management now guides for a double-digit revenue rebound in the first half of FY27.
— 4 earlier stories on Concord Biotech Ltd. →What's new
- Management forecasts a return to double-digit revenue growth in FY27, targeting its historical ~18% growth rate.
- Customer demand is normalising, with installed capacity to support ₹3,000 crore in revenue.
- New solar capacity is expected to deliver ~1-1.5% EBITDA savings, while US subsidiary start-up costs are fully absorbed.
Why this matters
The guidance marks a clear pivot after a year where supply-chain freezes eroded both top and bottom lines. Concord is betting its zero-debt balance sheet and new launches will drive the recovery. The pace hinges on geopolitical headwinds fully unwinding.
What we're watching
- First-half order book to confirm the demand normalisation is real.
- Margin progression as solar savings and US subsidiary costs fall away.
- Execution on new product launches against a weak base year.
The full read
Concord Biotech's FY26 was a reset. Revenue fell 12% and net profit dropped 30% to ₹259 crore as geopolitical flare-ups and logistics bottlenecks froze demand. Management now expects a rebound to double-digit growth in FY27, citing first-half visibility as demand normalises. The company has the headroom to deliver. Its installed capacity can support ₹3,000 crore in revenue, versus its current run-rate. On the margin side, new solar assets should save ~1-1.5% on EBITDA, while the US subsidiary and injectables unit are past the cost-absorption phase. The balance sheet is clean, with zero debt to fund the ramp. The guidance is confident. The open question is how quickly geopolitical headwinds fully unwind.
Questions answered
- Why did Concord Biotech's profit fall so sharply in FY26?
- Net profit dropped 30% to ₹259 crore because revenue declined 12%. The cause was geopolitical disruptions and supply-chain delays that weighed on customer demand.
- What is the company's capacity ceiling?
- Management said installed capacity can support ₹3,000 crore in revenue, which is well above its current scale. This gives it room to grow without major new capital expenditure.
- Where do the expected margin improvements come from?
- Concord expects ~1-1.5% EBITDA gains from new solar energy assets. It also expects further gains from its injectables business and a US subsidiary where all start-up costs are now absorbed.
- What is the company's financial position to fund the rebound?
- The company has a zero-debt balance sheet. This gives it the financial flexibility to invest in capacity and new product launches without needing external financing.
Story so far
All notes on CONCORDBIO →- 5 Jun 2026 · 6:37 PM IST Concord Biotech expects growth to return in FY27 after profit dropped 30%
- 3d ago Concord Biotech wins USFDA nod for generic transplant drug
- 7d ago Concord Biotech's profit falls 30% on a 12% revenue slide
- 7d ago Concord Biotech profit drops 30% on 11% revenue fall
- 7d ago Concord Biotech profit falls 30% as revenue shrinks in FY26